Exhibit 16.1
June 14, 2018
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
We have read the statements of CannaPharmaRX, Inc., pertaining to our firm included under Item 4.01 of Form 8-K dated April 20, 2018 and agree with such statements as they pertain to our firm.
Sincerely,
/s/ KLJ & Associates, LLP